Compass Therapeutics Announced At ESMO Saturday Phase 2/3 COMPANION-002 Tovecimig Plus Paclitaxel Met Primary ORR, Key Secondary PFS Endpoints In Advanced Biliary Tract Cancer, Reducing Progression Or Death Risk By 56%, With 62.2% Disease Control Rate Vs. 36.8%

Loading news article.

Compass Therapeutics Announced At ESMO Saturday Phase 2/3 COMPANION-002 Tovecimig Plus Paclitaxel Met Primary ORR, Key Secondary PFS Endpoints In Advanced Biliary Tract Cancer, Reducing Progression Or Death Risk By 56%, With 62.2% Disease Control Rate Vs. 36.8% | WAPE

Compass Therapeutics Announced At ESMO Saturday Phase 2/3 COMPANION-002 Tovecimig Plus Paclitaxel Met Primary ORR, Key Secondary PFS Endpoints In Advanced Biliary Tract Cancer, Reducing Progression Or Death Risk By 56%, With 62.2% Disease Control Rate Vs. 36.8%

Article summary

Related companies

Analyzed by WAPE AI.

Comments —